Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

PURPOSE: Genomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors. Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan‑RAF inhibitor. This first-in-human phase 1 study explored the safety and antitumor activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasco, Drew W., Medina, Theresa, Corrie, Pippa, Pavlick, Anna C., Middleton, Mark R., Lorigan, Paul, Hebert, Chris, Plummer, Ruth, Larkin, James, Agarwala, Sanjiv S., Daud, Adil I., Qiu, Jiaheng, Bozon, Viviana, Kneissl, Michelle, Barry, Elly, Olszanski, Anthony J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261210/
https://www.ncbi.nlm.nih.gov/pubmed/37219686
http://dx.doi.org/10.1007/s00280-023-04544-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261210/
https://www.ncbi.nlm.nih.gov/pubmed/37219686
http://dx.doi.org/10.1007/s00280-023-04544-5

Ejemplares similares